Steroid-induced diabetes in rheumatologic patients

Clinical and Experimental Rheumatology

Volumn 32, Issue 1, 2014, Pages 126-130

  Angelopoulos, Theodoros P ^a   Tentolouris, Nikolaos K ^b   Bertsias, George K ^c   Boumpas, Dimitrios T ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Cardiovascular risk; Diabetes; Glucocorticoids; Hyperglycaemia; Rheumatologic patients

Indexed keywords

ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GLUCOCORTICOIDS; HUMANS; INSULIN RESISTANCE; PROGNOSIS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84894106480     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. American Diabetes Association: Standards of medical care in Diabetes-2013. Diabetes Care 2013; 36: S11-S66.
2. INZUCCHI SE: Diagnosis of diabetes. N Engl J Med 2012; 367: 542-50.
3. PANTHAKALAM S, BHATNAGAR D, KLIMIUK P: The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004; 49: 139-141.
4. UZU T, HARADA T, SAKAGUCHI M et al.: Glucocorticoid induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007; 105: c54-c57.
5. IWAMOTO T, KAGAWA Y, NAITO Y, KUZUHARA S, KOJIMA M: Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004; 24: 508-14.
6. GULLIFORD MC, CHARLTON J, LATINOVIC R: Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006; 29: 2728-9.
7. GURWITZ JH, BOHN RL, GLYNN RJ, MONANE M, MOGUN H, AVORN J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101.
8. BLACKBURN D, HUX J, MAMDANI M: Quantification of the risk of corticosteroidinduced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17: 717-20.
9. CONN HO, POYNARD T: Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619-32.
10. SIMMONS L, MOLYNEAUX L, YUE DK, CHUA EL: Steroid-induced diabetes: is it just unmasking of type 2 diabetes?. ISRN Endocrinol 2012; 2012: 910905.
11. TENTOLOURIS N, KATSILAMBROS N: Type 2 diabetes: an overview. In: JOHN C. PICKUP & GARETH WILLIAMS (Eds.) Textbook of Diabetes, 3rd ed. Blackwell Publishing; Oxford, UK, 2003; 4.1-4.19.
12. RIZZA RA, MANDARINO LJ, GERICH JE: Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982; 54: 131-8.
13. JONES C, HOTHI S, TITHERADGE M: Effect of dexamethasone on gluconeogenesis, pyruvate kinase, pyruvate carboxylase and pyruvate dehydrogenase flux in isolated hepatocytes. Biochem J 1993; 289: 821-8.
14. ǍTSUMOTO K, YAMASAKI H, AKAZAWA S et al.: High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996; 81: 2621-6.
15. CERIELLO A, ESPOSITO K, PICONI L et al.: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-54.
16. MAGEE MH, BLUM RA, LATES CD, JUSKO WJ: Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001; 41: 1180-94.
17. TÓTH GG, KLOOSTERMAN C, UGES DR, JONKMAN MF: Pharmacokinetics of highdose oral and intravenous dexamethasone. Ther Drug Monit 1999; 21: 532-5.
18. GUSTAVSON SM, SANDOVAL DA, ERTL AC, BAO S, RAJ SR, DAVIS SN: Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab 2008; 294: E506-E512.
19. MIRANDA-FILLOY JA, LLORCA J, CARNEROLÓPEZ B, GONZÁLEZ-JUANATEY C, BLANCO R, GONZÁLEZ-GAY MA: TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012; 30: 850-5.
20. HOLMAN RR, THORNE KI, FARMER AJ et al.: (4-T Study Group). Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-30.
21. NUSSINOVITCH U, de CARVALHO JF, PEREIRA RM, SHOENFELD Y: Glucocorticoids and the cardiovascular system: state of the art. Curr Pharm Des 2010; 16: 3574-85.
22. REYNOLDS RM, LABAD J, SEARS AV et al.: Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study. Eur J Endocrinol 2012; 166: 861-8.
23. GONZALEZ-GAY MA: Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic diseases: myth or reality? Arthritis Rheum 2007; 57: 191-2.
24. HWANG YG, SAAG K: The safety of low-dose glucocorticoids in rheumatic diseases. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S104-S112.
25. STROHMAYER EA, KRAKOFF LR: Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am 2011; 40: 409-17.
26. BAKKER MF, JACOBS JW, WELSING PM et al.: Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156: 329-39.
27. GONZALEZ-JUANATEY C, TESTA A, GARCIACASTELO A et al.: Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004; 33: 231-8.
28. GONZALEZ-JUANATEY C, TESTA A, GARCIACASTELO A et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
29. GONZALEZ-JUANATEY C, LLORCA J, TESTA A, REVUELTA J, GARCIA-PORRUA C, GONZALEZ- GAY MA: Increased prevalence of severe subclinical atherosclerotic findings in longterm treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407-13.
30. MARADIT KREMERS H, REINALDA MS, CROWSON CS, DAVIS JM III, HUNDER GG, GABRIEL SE: Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007; 57: 279-86.